Eisai to buy TorreyPines' Alzheimer's genetic research
This article was originally published in Scrip
Eisaihas ended its collaborations with TorreyPines Therapeutics for basic research into the genetic mechanisms of Alzheimer's disease, and is to acquire all data and assets from the programmes. These looked at genes related to late-onset disease (which ended in September 2005) and whole-genome screening to elucidate pathogenesis (this September). Eisai will pay an undisclosed cash amount to the US firm, which is looking to progress several clinical-stage programmes. TorreyPines is also working on in-house gamma secretase modulators for Alzheimer's, for which it is seeking a development partner.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.